Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
a study on Amyotropic Lateral Sclerosis (ALS)
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at Orange, California and other locations
- Dates
- start:end: about
Description
Summary
This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
Official Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)
Details
Participants will be randomized to 1 of 2 treatment groups: PTC857 or matching placebo. Following successful completion of the Treatment Period, participants who enter the LTE Period, will receive open-label PTC857 for 28 weeks. Following completion of the LTE period, participants who enter the Continued LTE Period will receive open-label PTC857 for an additional 108 weeks.
Keywords
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Sclerosis, PTC857
Eligibility
You can join if…
Open to people ages 18-80
- ALS with preserved function, defined as:
- Onset of the first symptom leading to the diagnosis of ALS ≤24 months at the time of the initial Screening Visit
- Revised EL Escorial criteria of either:
(i) Clinically definite ALS (ii) Clinically probable ALS
- A total ALSFRS-R score of at least 34 at the start of the Screening Period
- No significant respiratory compromise as evidenced by slow vital capacity ≥60% at the start of the Screening Period
- All chronic concomitant medications (both prescription and over the counter), and non-pharmacologic therapy regimens, excluding standard-of-care therapy riluzole, edaravone, or sodium phenylbutyrate/taurursodiol, should be stable and unchanged from 14 days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study
- Female participants must have a negative breast cancer imaging screening status (not considered clinically abnormal and/or requiring further evaluation/treatment) within 6 months prior to the Screening Visit, or during the Screening Period.
- Standard-of-care therapy for the treatment of ALS (riluzole, edaravone, or sodium phenylbutyrate/taurursodiol) should be stable and unchanged from 30 (-3) days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study.
You CAN'T join if...
- Females who are pregnant or nursing or plan to become pregnant during the study
- Participants with clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular/ischemic disease or any other condition that, in the opinion of the investigator would jeopardize the safety of the participant or impact the validity of the study results
- Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator or the medical monitor, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant
- Current participation in any other investigational study with an investigational product or participation within 30 days prior to the start of the Screening Period or 5 half-lives of the previously taken investigational drug, whichever is longer
- Participant has previously received PTC857
- Participant is receiving a combination of edaravone and sodium phenylbutyrate/taurursodiol treatment, where applicable, within 30 days prior to the start of the Screening Period
- For female participants, any past medical history of breast cancer, regardless of remission status, or any first degree relative with history of breast cancer
Locations
- UC Irvine Health ALS and Neuromuscular Center
accepting new patients
Orange California 92868 United States - Forbes Norris MDA/ALS Research Center at California Pacific Medical Center
accepting new patients
San Francisco California 94109 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- PTC Therapeutics
- ID
- NCT05349721
- Phase
- Phase 2 Amyotropic Lateral Sclerosis (ALS) Research Study
- Study Type
- Interventional
- Participants
- Expecting 258 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.